SCHEMBL28349038

SCHEMBL28349038

COc1cc2ncnc(Oc3ccc(C(C(N)=O)n4cc(C(C)C)nn4)cc3)c2cc1OC

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 11/20 0.50
▸ PDGFRA P16234 1/20 0.49
▸ PDGFRB P09619 4/20 0.49
▸ FLT4 P35916 4/20 0.49
▸ FLT3 P36888 3/20 0.49
▸ CSF1R P07333 2/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ AURKA O14965 1/20 0.48
▸ MET P08581 1/20 0.48
▸ TEK Q02763 1/20 0.48
▸ AURKB Q96GD4 1/20 0.48
▸ BRAF P15056 4/20 0.47
▸ RAF1 P04049 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30407691 0.76 KDR (0.62) KDRPDGFRAPDGFRBFLT4FLT3
SCHEMBL20547581 0.76 KDR (0.62) KDRPDGFRAPDGFRBFLT4FLT3
SCHEMBL26102003 0.74 EGFR (0.39) KDRPDGFRAPDGFRBFLT4FLT3
SCHEMBL26103100 0.74 PIK3CD (0.41) KDRPDGFRAPDGFRBFLT3
SCHEMBL14967551 0.73 KDR (0.67) KDRPDGFRAPDGFRBFLT4CSF1R
SCHEMBL26100989 0.73 KDR (0.39) KDRPDGFRAPDGFRBFLT4FLT3
SCHEMBL20547350 0.73 PDGFRB (0.55) KDRPDGFRAPDGFRBFLT4FLT3
SCHEMBL30408200 0.73 PDGFRB (0.55) KDRPDGFRAPDGFRBFLT4FLT3
SCHEMBL20548339 0.73 KDR (0.57) KDRPDGFRAPDGFRBFLT4FLT3
SCHEMBL30407674 0.73 KDR (0.57) KDRPDGFRAPDGFRBFLT4FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110546147-A Phenoxyquinazoline compounds and their use in the treatment of cancer ASTRAZENECA AB 2019-12-06 — — CN claimed
CN-110546147-A Phenoxyquinazoline compounds and their use in the treatment of cancer ASTRAZENECA AB 2019-12-06 — — CN disclosed
Send feedback